Aldose Reductase Is Involved in the Development of Murine Diet-Induced Nonalcoholic Steatohepatitis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Qiu, Longxin ^a   Lin, Jianhui ^a   Ying, Miao ^a   Chen, Weiqiang ^a   Yang, Jinmei ^a   Deng, Tiantian ^a   Chen, Jinfeng ^a   Shi, Duanyu ^a   Yang, James Y ^b  

^a LONGYAN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDEHYDE REDUCTASE; CHOLINE; COLLAGEN; CYTOCHROME P450 2E1; CYTOKINE; GELATINASE A; INTERLEUKIN 6; LENTIVIRUS VECTOR; LIPID PEROXIDE; MESSENGER RNA; METHIONINE; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; DIET; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REPRESSION; FIBROGENESIS; FIBROSIS; GENE; GENE EXPRESSION; GENE SILENCING; LIVER CELL; LIVER FIBROSIS; MMP2 GENE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; TIMP1 GENE;

ALDEHYDE REDUCTASE; ANIMALS; BLOTTING, WESTERN; CHOLINE; DIET; FATTY LIVER; FEMALE; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; METHIONINE; MICE; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884182149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073591     Document Type: Article

References (38)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ, (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438.
2. Larter CZ, Farrell GC, (2006) Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 44: 253-261.
3. Voican CS, Perlemuter G, (2011) Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis. J Hepatol 54: 388-391.
4. Carter-Kent C, Zein NN, Feldstein AE, (2008) Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 103: 1036-1042.
5. Koek GH, Liedorp PR, Bast A, (2011) The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 412: 1297-1305.
6. Clements RS Jr, (1986) The polyol pathway. A historical review. Drugs 32Suppl 2: 3-5.
7. O'Connor T, Ireland LS, Harrison DJ, Hayes JD, (1999) Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J 343 Pt 2: 487-504.
8. Takahashi M, Hoshi A, Fujii J, Miyoshi E, Kasahara T, et al. (1996) Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. Jpn J Cancer Res 87: 337-341.
9. Brown KE, Broadhurst KA, Mathahs MM, Kladney RD, Fimmel CJ, et al. (2005) Immunodetection of aldose reductase in normal and diseased human liver. Histol Histopathol 20: 429-436.
10. Qiu L, Lin J, Xu F, Gao Y, Zhang C, et al. (2011) Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-alpha and ameliorates hepatosteatosis in diabetic db/db mice. Exp Diabetes Res 2012: 789730.
11. Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, et al. (2004) Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287: G1035-1043.
12. Ip E, Farrell G, Hall P, Robertson G, Leclercq I, (2004) Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39: 1286-1296.
13. Shen B, Yu J, Wang S, Chu ES, Wong VW, et al. (2008) Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology 47: 473-483.
14. Brunt EM, (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21: 3-16.
15. Qiu L, Wu X, Chau JF, Szeto IY, Tam WY, et al. (2008) Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis. J Biol Chem 283: 17175-17183.
16. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, et al. (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105: 1067-1075.
17. Robertson G, Leclercq I, Farrell GC, (2001) Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281: G1135-1139.
18. Vander Jagt DL, Kolb NS, Vander Jagt TJ, Chino J, Martinez FJ, et al. (1995) Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 1249: 117-126.
19. Esterbauer H, Schaur RJ, Zollner H, (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128.
20. Spycher S, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A, (1996) 4-hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase. Biochem Biophys Res Commun 226: 512-516.
21. Rittner HL, Hafner V, Klimiuk PA, Szweda LI, Goronzy JJ, et al. (1999) Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 103: 1007-1013.
22. Ruef J, Liu SQ, Bode C, Tocchi M, Srivastava S, et al. (2000) Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler Thromb Vasc Biol 20: 1745-1752.
23. Tracey WR, Magee WP, Ellery CA, MacAndrew JT, Smith AH, et al. (2000) Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol 279: H1447-1452.
24. Yadav UC, Ramana KV, Aguilera-Aguirre L, Boldogh I, Boulares HA, et al. (2009) Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice. PLoS One 4: e6535.
25. Yadav UC, Srivastava SK, Ramana KV, (2007) Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 48: 4634-4642.
26. Nieto N, Friedman SL, Cederbaum AI, (2002) Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 277: 9853-9864.
27. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, et al. (2001) Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34: 1158-1163.
28. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, et al. (2006) Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55: 415-424.
29. Memon RA, Grunfeld C, Feingold KR, (2001) TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat Med 7: 2-3.
30. Deng QG, She H, Cheng JH, French SW, Koop DR, et al. (2005) Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42: 905-914.
31. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B, (2004) IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 1: 205-211.
32. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, et al. (2004) Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40: 933-941.
33. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, et al. (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103: 1372-1379.
34. Tamasi V, Miller KK, Ripp SL, Vila E, Geoghagen TE, et al. (2008) Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators. Mol Pharmacol 73: 968-976.
35. Kristensen DB, Kawada N, Imamura K, Miyamoto Y, Tateno C, et al. (2000) Proteome analysis of rat hepatic stellate cells. Hepatology 32: 268-277.
36. Parola M, Pinzani M, Casini A, Leonarduzzi G, Marra F, et al. (1996) Induction of procollagen type I gene expression and synthesis in human hepatic stellate cells by 4-hydroxy-2,3-nonenal and other 4-hydroxy-2,3-alkenals is related to their molecular structure. Biochem Biophys Res Commun 222: 261-264.
37. Poulos JE, Weber JD, Bellezzo JM, Di Bisceglie AM, Britton RS, et al. (1997) Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. Am J Physiol 273: G804-811.
38. Toda K, Kumagai N, Tsuchimoto K, Inagaki H, Suzuki T, et al. (2000) Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis. J Gastroenterol 35: 214-220.